Amryt Pharma Overview
- Founded
-
2004
- Status
-
Public
- Employees
-
289
- Stock Symbol
-
AMYT.GB
- Investments
-
6
Amryt Pharma General Information
Description
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
Contact Information
Website
www.amrytpharma.com
Formerly Known As
Amryt Pharmaceuticals Designated Activity Company
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Stock Exchange
NEXX
Primary Office
- 196 High Road Wood Green
- 1 Adam Street
- London N22 8HH
- England, United Kingdom
Amryt Pharma Timeline
Amryt Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| Revenue | 233,240 | 222,543 | 182,607 | 58,124 |
| EBITDA | 65,543 | 67,637 | (39,143) | (42,823) |
| Net Income | 3,046 | 1,000 | (104,527) | (62,998) |
| Total Assets | 786,867 | 816,057 | 536,591 | 527,096 |
| Total Debt | 206,463 | 199,183 | 189,351 | 180,090 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Amryt Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amryt Pharma Executive Team (10)
Amryt Pharma Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000 00.0 | Self | Board Member | 000 0000 |
| 000000 00000 00 | Amryt Pharma | Board Member | 000 0000 |
| 000000 0000000 | Self | Board Member | 000 0000 |
| 000000 00000 | Amryt Pharma | Founder, Chief Executive Officer & Board Member | 000 0000 |
| 0000000 0000 00 | Amryt Pharma | Board Member | 000 0000 |
Amryt Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Amryt Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Amryt Pharma Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 05-Aug-2021 | 0000000000 | 00000 | Drug Delivery | 000000 00 |
| 0000 0000000 | 12-Oct-2020 | 0000000000 | 00000 | Biotechnology | |
| 00000000 0000 | 24-Sep-2019 | 0000000000 | 00000 | Biotechnology | 000000 00 |
| 000000 (00000 | 18-Apr-2016 | 0000000000 | 000.00 | Drug Discovery | |
| Fastnet Equity | 18-Apr-2016 | Merger/Acquisition | 000.00 | Energy Exploration |
Amryt Pharma Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000 | Drug Delivery | Needham, MA | 0000 |